{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:43:20Z","timestamp":1774593800697,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Purpose: Opioids are widely used for pain management but are associated with adverse events that may differ between women and men. However, post-marketing safety data are rarely examined at the individual level to characterize these sex differences. This study aimed to identify sex disparities in opioid-associated adverse events using the FDA Adverse Event Reporting System (FAERS) to inform safer opioid selection for women. Methods: Opioid drugs were identified using the FDA\u2019s Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) list and official drug labeling. Relevant FAERS reports were extracted, and adverse events were classified into 27 System Organ Classes (SOCs) based on the Medical Dictionary for Regulatory Activities (MedDRA). Sex-specific signals of disproportionate reporting were evaluated using proportional reporting ratios and reporting odds ratios for drug\u2013SOC pairs. Results: Across most opioid drugs and SOCs, adverse events were reported more frequently in women than in men. The largest sex disparities were observed for codeine, fentanyl, tapentadol, hydrocodone, and sufentanil, with significantly higher disproportionate reporting rates among women. These findings indicate pronounced sex-specific differences in the post-marketing safety profiles of several commonly used opioids. Conclusions: Women demonstrate higher disproportionate reporting of adverse events for certain opioid medications, particularly codeine and fentanyl. These results suggest the need for increased awareness of sex-specific safety differences and support sex-informed prescribing and monitoring strategies to improve opioid safety in women. Since pharmacists are medication experts and play a key role in promoting rational and safe use, our findings may further support pharmacists counseling patients and monitoring for opioid-related adverse events.<\/jats:p>","DOI":"10.3390\/ph19040526","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:07:13Z","timestamp":1774433233000},"page":"526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Sex Differences in Adverse Events Reported on Opioid Drugs in the FDA\u2019s Adverse Event Reporting System (FAERS)"],"prefix":"10.3390","volume":"19","author":[{"given":"Aasma","family":"Aslam","sequence":"first","affiliation":[{"name":"National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-3968","authenticated-orcid":false,"given":"Huixiao","family":"Hong","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tucker A.","family":"Patterson","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Guo","sequence":"additional","affiliation":[{"name":"National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"ref_1","unstructured":"(2025, June 01). Available online: https:\/\/www.cdc.gov\/nchs\/pressroom\/releases\/20240515.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.prcp.20190051","article-title":"Opioid Use Disorder in Women and the Implications for Treatment","volume":"3","author":"Campbell","year":"2021","journal-title":"Psychiatr. Res. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40122-021-00244-1","article-title":"Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization","volume":"10","author":"Casale","year":"2021","journal-title":"Pain Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40122-017-0084-3","article-title":"Why We Still Need To Speak About Sex Differences and Sex Hormones in Pain","volume":"6","author":"Aloisi","year":"2017","journal-title":"Pain Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.yfrne.2013.06.001","article-title":"Estrogenic influences in pain processing","volume":"34","author":"Amandusson","year":"2013","journal-title":"Front. Neuroendocr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13293-021-00364-5","article-title":"Estrogen receptors in pain modulation: Cellular signaling","volume":"12","author":"Chen","year":"2021","journal-title":"Biol. Sex Differ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s11606-019-05242-w","article-title":"Menopausal Symptoms and Higher Risk Opioid Prescribing in a National Sample of Women Veterans with Chronic Pain","volume":"34","author":"Gibson","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and Treatment of Opioid Misuse and Addiction: A Review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ALN.0000000000003705","article-title":"Opioid-free Anesthesia: Time to Regain Our Balance","volume":"134","author":"Kharasch","year":"2021","journal-title":"Anesthesiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ajg.2011.30","article-title":"Opioid-induced constipation: Challenges and therapeutic opportunities","volume":"106","author":"Camilleri","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2796.2006.01667.x","article-title":"Fracture risk associated with the use of morphine and opiates","volume":"260","author":"Vestergaard","year":"2006","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1038\/s41598-021-93500-5","article-title":"Informing selection of drugs for COVID-19 treatment through adverse events analysis","volume":"11","author":"Guo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_14","unstructured":"(2025, June 01). FDA Labeling, Available online: https:\/\/www.fda.gov\/science-research\/bioinformatics-tools\/fdalabel-full-text-search-drug-product-labeling."},{"key":"ref_15","unstructured":"FDA (2024, April 09). FDA Established Pharmacologic Class (EPC), Available online: https:\/\/www.fda.gov\/industry\/structured-product-labeling-resources\/pharmacologic-class."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/pm\/pnx247","article-title":"Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users","volume":"19","author":"Mickle","year":"2018","journal-title":"Pain Med."},{"key":"ref_17","first-page":"e1266","article-title":"Occurrence of Opioid-Related Neurocognitive Symptoms Associated With Long-term Opioid Therapy","volume":"41","author":"Sung","year":"2025","journal-title":"Clin. J. Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e044157","DOI":"10.1136\/bmjopen-2020-044157","article-title":"Sex differences in type and occurrence of adverse reactions to opioid analgesics: A retrospective cohort study","volume":"11","author":"Lopes","year":"2021","journal-title":"BMJ Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-024-01433-9","article-title":"Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision Dosing","volume":"63","author":"Ashraf","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","first-page":"71","article-title":"Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics","volume":"13","author":"Lopes","year":"2020","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bcp.13129","article-title":"A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients","volume":"83","author":"Kuip","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol. Sex Differ."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Giovannini, E., Bonasoni, M.P., Pascali, J.P., Bini, C., Pelletti, G., Gualandi, A., Dal Lago, G., Mercati, A., Mariotti, B., and Pasini, G.P. (2024). Fetal and Infant Effects of Maternal Opioid Use during Pregnancy: A Literature Review including Clinical, Toxicological, Pharmacogenomic, and Epigenetic Aspects for Forensic Evaluation. Children, 11.","DOI":"10.3390\/children11030278"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11920-019-1110-4","article-title":"Opioid Use in Pregnancy","volume":"21","author":"Tobon","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2012.3951","article-title":"Neonatal Abstinence Syndrome and Associated Health Care Expenditures: United States, 2000\u20132009","volume":"307","author":"Patrick","year":"2012","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bpobgyn.2022.07.008","article-title":"Epidemiology of opioid use in pregnancy","volume":"85","author":"Cook","year":"2022","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_28","first-page":"33","article-title":"Safety of codeine during breastfeeding: Fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine","volume":"53","author":"Madadi","year":"2007","journal-title":"Can. Fam. Physician"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/endrev\/bnae023","article-title":"Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement","volume":"45","author":"Karavitaki","year":"2024","journal-title":"Endocr. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1210\/er.2009-0009","article-title":"The effects of opioids and opioid analogs on animal and human endocrine systems","volume":"31","author":"Vuong","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"c4462","DOI":"10.1136\/bmj.c4462","article-title":"Opioid induced hypogonadism","volume":"341","author":"Reddy","year":"2010","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2329074","DOI":"10.1001\/jamanetworkopen.2023.29074","article-title":"Adverse Drug Events by Sex After Adjusting for Baseline Rates of Drug Use","volume":"6","author":"Rushovich","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108085","DOI":"10.1016\/j.amepre.2025.108085","article-title":"Risks for Adverse Events by Sex and Age After Prescription Opioid Dose Reduction: A Secondary Analysis Across 8 U.S. Health Systems","volume":"69","author":"Metz","year":"2025","journal-title":"Am. J. Prev. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpain.2008.12.001","article-title":"Sex, gender, and pain: A review of recent clinical and experimental findings","volume":"10","author":"Fillingim","year":"2009","journal-title":"J. Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1111\/bcp.16218","article-title":"Sex differences in comorbid pain and opioid use disorder: A scoping review","volume":"90","author":"DeVito","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Han, C., Manners, M.T., and Robinson, S.A. (2024). Sex differences in opioid response: A role for the gut microbiome?. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1455416"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00210-025-04721-8","article-title":"Biological sex differences in pharmacokinetics and adverse drug reactions","volume":"399","author":"Aljohmani","year":"2026","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/15409996251369454","article-title":"Sex Differences in Opioid-Related Mortality Trends in the United States, 1999\u20132020: By Age, Race\/Ethnicity, Region, and Opioid Type","volume":"34","author":"Khandaker","year":"2025","journal-title":"J. Women Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00127-021-02199-2","article-title":"Mental disorder and opioid overdose: A systematic review","volume":"57","author":"Tsang","year":"2022","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"ref_43","unstructured":"Ara\u00fajo, M., Mendes-Frias, A., and Silvestre, R. Sex differences in immune modulation: Implications for infection, inflammation, and nutritional supplementation. Biol. Sex Differ., Online ahead of print."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2464942","DOI":"10.1080\/19490976.2025.2464942","article-title":"Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure","volume":"17","author":"Singh","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_45","unstructured":"(2025, June 01). REMS, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?REMS=17&event=RemsDetails.page&utm_medium=email&utm_source=govdelivery."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2023). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:16:04Z","timestamp":1774588564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ph19040526"],"URL":"https:\/\/doi.org\/10.3390\/ph19040526","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}